Bioheng Therapeutics

Bioheng Therapeutics is a clinical stage company focused on allogeneic / off-the-shelf CAR-T. Founded in 2017, we aim to develop the world’s leading allogeneic cell therapy products to address some of the most challenging the unmet needs. In March 2020, Bioheng received IND approval for CTA101, marking the first UCAR-T IND in China. In January 2023, our CD7-targeted UCAR-T, CTD401, received Orphan Drug Designation (ODD) from the U.S. FDA for the treatment of T-ALL. This groundbreaking product is based on Bioheng's next-generation, novel, and proprietary UCAR-T technology platform—ANSWER CAR. As Bioheng's flagship asset, the CD7 UCAR-T has been dosed in nearly a hundred patients in an Investigator-Initiated Trial (IIT) clinical study, demonstrating excellent efficacy and safety. We are advancing the global clinical trial for this pipeline.